|
Characteristics of patients and treatments |
||
| Parameter |
Methotrexate |
All other DMARDs |
|
|
||
| Number |
86 |
77 |
| Age (years [mean ± SD]) |
60.7 ± 12.9 |
63.6 ± 11.9 |
| Rheumatoid Factor (% positive) |
70.9% |
64.9% |
| Sex (% female) |
86.0% |
79.2% |
| Disease duration (years [mean ± SD]; oMTX/rMTX) |
9.5 ± 8.3/13.3 ± 8.6 |
7.5 ± 8.5/12.6 ± 8.6 |
| Prior DMARDs (median [range]; oMTX/rMTX) |
1 (0–6)/4 (2–9) |
1 (0–8)/3 (2–10) |
| Baseline dose (mg/week [median (1st-3rd quartile)]; oMTX/rMTX) |
10.0 (7.5–15.0)/15.0 (10.0–20.0) |
-/- |
| Base line CRP (mg/l [mean ± SD]; oMTX/rMTX) |
33.4 ± 26.2/29.1 ± 31.0 |
15.2 ± 16.8/18.3 ± 23.0 |
| Base line ESR (mm/hour [mean ± SD]; oMTX/rMTX) |
47.0 ± 30.0/35.0 ± 22.0 |
30 ± 13/32 ± 22 |
|
CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; oMTX, original methotrexate course; rMTX, re-employed methotrexate course; SD, standard deviation. | ||
Kapral et al. Arthritis Research & Therapy 2006 8:R46 doi:10.1186/ar1902 |
||